Jorge reis filho metastatic cancer
HER2-Low Expression is the Tip of the Iceberg in Breast ...
Jorge Reis-Filho -
- As the VP of Cancer Biomarker Development, I lead a dedicated team focused on developing and validating cutting-edge biomarkers for patient selection and therapeutic response prediction.
12 Questions with Jorge Reis-Filho - pharmaphorum
12 Questions with Jorge Reis-Filho
As Vice President of Cancer Biomarker Development at AstraZeneca, Jorge Reis-Filho seeks to develop and validate the next generation of mechanistically informed and clinically deployable biomarkers and to facilitate access to optimal treatments for cancer patients worldwide.
What are the main responsibilities of your current role? I oversee development of the next generation of cancer biomarkers. My primary focus is creating mechanistically informed and clinically deployable biomarkers to help deliver the right drug to the right patient at the right time in their therapeutic journey. My team and I are responsible for building the technologies, approaches, systems, and assays that can unlock the full potential of precision and personalised medicine.
What was your background prior to this role and how did it prepare you for the work you do now? My career has been rather unorthodox. Starting in academia in 2002 as a patho
Plasma DNA Analysis in the Management of Breast Cancer ...
- With a background in molecular pathology, bioinformatics, functional genomics and artificial intelligence, I have pioneered innovative methods to decipher cancer genomics, intra-tumour genetic heterogeneity and DNA repair defects.
Jorge Reis-Filho: A great opportunity to learn more about the ...
Jorge Reis-Filho - Vice President, Cancer Biomarker ...
Pathogenesis of Triple-Negative Breast Cancer - Annual Reviews
Synapse - Jorge Reis-Filho - Memorial Sloan Kettering Cancer ...
- Reis-Filho has contributed to the use of methods for circulating cell-free tumor DNA in plasma in breast cancer and to the development of ‘high-intensity’ assays for breast cancer detection and monitoring.
| 1,✉, Jorge S Reis-Filho. | |
| With a background in molecular pathology, bioinformatics, functional genomics and artificial intelligence, I have pioneered innovative methods to decipher cancer genomics, intra-tumour genetic heterogeneity and DNA repair defects. | |
| A report of the International Immuno‐oncology Biomarker Working Group on Breast Cancer. |
Jorge S. Reis-Filho, MD PhD FRCPath - The Lobular Breast ...
- As Vice President of Cancer Biomarker Development at AstraZeneca, Jorge Reis-Filho seeks to develop and validate the next generation of mechanistically informed and clinically deployable.